Blog

Katy Beckermann: Feasibility of an intermittent ipi/nivo approach in their Phase II trial

Photo taken from medschool.vanderbilt.edu

Aug 30, 2024, 16:32

Katy Beckermann: Feasibility of an intermittent ipi/nivo approach in their Phase II trial

Katy Beckermann, Assistant Professor Of Medicine, Vanderbilt University Medical Center, shared a post on X:

“Congrats to Moshe Ornstein, MD and team for demonstrating the feasibility of an intermittent ipi/nivo approach in their Phase II trial, showing potential for prolonged treatment-free intervals. Looking forward to more studies like this.”

Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab

Authors: Moshe C. Ornstein, Laeth George, Wei Wei, C. Marcela Diaz-Montero, Pat Rayman, Allison Martin, Arnab Basu, Kathryn E.

Beckermann, Amanda Nizam, Christopher E. Wee, Timothy D. Gilligan, Shilpa Gupta, Brian I. Rini

Additional information
Source: Katy Beckermann/X

Academic clinical trials Allison Martin Amanda Nizam Arnab Basu Brian I. Rini C. Marcela Diaz-Montero cancer Christopher E. Wee Kathryn E. Beckermann Katy Beckermann Laeth George Moshe C. Ornstein Moshe Ornstein OncoDaily Oncology Pat Rayman Shilpa Gupta Timothy D. Gilligan Vanderbilt University Medical Center Wei Wei

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage